Onconetix (ONCO) Stock: Buy, Sell, or Hold?
ONCO - Onconetix, Inc. Common Stock
$0.41
-0.03 (-6.18%)
▼
5d:
-25.49%
30d:
-55.13%
90d:
-50.28%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When ONCO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ONCO is down 25.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ONCO is down 25.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ONCO is currently trading at $0.41, which is considered oversold relative to its 30-day fair value range of $0.49 to $0.83.
Technical Outlook: Technically, ONCO is in a strong downtrend. Immediate support is located at $0.38, while resistance sits at $0.64. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.00 (+1968.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONCO is in a strong downtrend. Immediate support is located at $0.38, while resistance sits at $0.64. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.00 (+1968.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.49 -
$0.83
Company Quality Score
50/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BEARISH: Downward momentum (-6.2%)
- BULLISH: Trading 1968.0% below Wall St target ($9.00)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.49 -
$0.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.38
Resistance Level
$0.64
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Wall Street Target
$9.00
(+1968.0%)
Revenue Growth (YoY)
-83.9%
Share & Embed Analysis
Last updated: October 22, 2026 3:35 PM ET
Data refreshes hourly during market hours. Next update: 4:35 PM
Data refreshes hourly during market hours. Next update: 4:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONCO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
